--(BUSINESS WIRE)--Cardium Therapeutics and its subsidiaries, InnerCool Therapies and Tissue Repair Company, are medical technology companies primarily focused on the development and commercialization of novel biologic therapeutics and medical devices for cardiovascular and ischemic disease. The company recently announced its lead product candidate, Generx is to be advanced to a Phase 3 clinical trial in women as a potential treatment for myocardial ischemia (insufficient blood flow within the heart muscle), following an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA).
